What’s the current market cap for Merck & Co. stock?

Merck & Co. (MRK) has a market cap of $298bn as of June 08, 2026.

What is the P/E ratio for Merck & Co. stock?

The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 33.78 as of June 08, 2026.

Does Merck & Co. stock pay dividends?

Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of June 08, 2026, the dividend rate is $3.32 and the yield is 2.81%. Merck & Co. has a payout ratio of 92.12% on a trailing twelve-month basis.

When is the next Merck & Co. dividend payment date?

The next Merck & Co. (MRK) dividend payment is scheduled for July 08, 2026.

What is the beta indicator for Merck & Co.?

Merck & Co. (MRK) has a beta rating of 0.22. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Merck & Co. stock | $MRK Share Price

About Merck & Co.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).

Ticker

$MRK

Sector

Health

Primary listing

NYSE

Employees

74,000

Headquarters

Rahway, United States

Website

www.merck.com

Merck & Co. Metrics

BasicAdvanced

$298bn

33.78

$3.58

0.22

$3.32

2.81%

What the Analysts think about Merck & Co.

Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.

Bulls say / Bears say

Merck & Co. reported first-quarter 2026 sales of $16.3 billion, topping analysts’ $15.8 billion estimate on the back of strong uptake of newer products like Winrevair and an injectable version of Keytruda, demonstrating robust demand beyond its legacy franchises. (Bloomberg)

CEO Rob Davis affirmed at the January 2026 JPMorgan Healthcare Conference that Merck has a robust balance sheet with capacity for “multi tens of billion”-dollar deals, positioning the company to enhance its pipeline through strategic acquisitions. (Bloomberg)

Despite heightened competition, Keytruda maintained strong momentum with $7.9 billion in sales in Q1 2026, securing its spot as the world’s second-best-selling drug and underpinning Merck’s core oncology franchise. (Bloomberg)

In Q1 2026, Eli Lilly’s Mounjaro overtook Merck’s Keytruda as the world’s top-selling drug, posting $8.7 billion versus Keytruda’s $7.9 billion, signaling intensifying competitive pressure on Merck’s flagship therapy. (Bloomberg)

Merck announced staff cuts impacting around 150 employees at its Durham, North Carolina, plant producing Gardasil amid a slump in global demand for its HPV vaccine, pointing to challenges in sustaining vaccine segment growth. (Bloomberg)

The launch of a dedicated biosimilars unit by Sandoz to target a $650 billion off-patent biologics market underscores looming generic and biosimilar competition that could erode Merck’s market share in key therapeutic areas. (Bloomberg)

Data summarised monthly by Lightyear AI. Last updated on 19 May 2026.

Merck & Co. Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Merck & Co. Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Merck & Co. News

AllArticlesVideos

Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Business Wire·6 days ago

Merck exec says company is discussing use of COVID antiviral drug in Ebola response

Reuters·1 week ago

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Business Wire·1 week ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.